Ladenburg Thalmann maintains PaySign at Buy, raises price target to $15.25 from $14

Ladenburg Thalmann maintained its Buy rating on PaySign and raised its price target to $15.25 from $14, an 8.9% increase. This implies a 50.4% upside from the Nov 10 close of $10.14.

Original reporting
Published Nov 11, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ladenburg Thalmann maintains PaySign at Buy, raises price target to $15.25 from $14 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The new target suggests a 50% upside from the recent close, but the micro‑cap's thin float may temper market reaction.

02

Market read

A modest analyst upgrade for a low‑cap fintech; limited broader market relevance.

03

What to watch

Liquidity and trading volume constraints could limit price move

Relevance 5/10Novelty 5/10Timing: post-market update

Background

Analyst Ladenburg Thalmann upgraded PaySign to Buy and lifted the price target from $14 to $15.25.

Market effects

minimal impact on fintech sector

none

low

Counterpoint

Target raise may be overly optimistic for a micro‑cap

Key entities

  • Ladenburg Thalmann

    Research firm issuing the rating and price target

  • PaySign

    Fintech firm subject of the rating upgrade

Related articles

$PAYSMedAI 8/10

Paysign (PAYS) Q3 2026 Earnings Call Transcript

Paysign (PAYS) reported Q3 2026 earnings, highlighting growth in its patient affordability business with revenue doubling to $16.6M YoY. Plasma revenue rose 7.5% to $13.8M. The company expects to offset a loss of 113 plasma centers with new clients. Patient affordability drove strong margins and operating leverage, while Apherion, a plasma industry software, is under regulatory review.

$PAYSHigh

Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8% Patient Affordability Growth Drives Revenue and Margin Expansion Raises Full Year 2026 Gross Margin, Net Income, GAAP EPS and Adju

$PAYSHigh

Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expense Discipline Continue to Drive Gross and Oper

$SPCXHigh

Good Time to Buy SpaceX Stock? Shares Hover Near IPO Price After Historic Starship Catch and Tesla Merger Buzz

SpaceX (SPCX) shares closed at $139.11, near their IPO price of $135, after a 0.6% drop. The company achieved a milestone by catching its Starship rocket's upper stage post-market. Shares have been volatile, influenced by Tesla merger speculation and AI sector trends. Analysts remain mostly optimistic, with average price targets around $250-$265, though risks include high valuation and heavy spending.